Syros Pharmaceuticals (NASDAQ:SYRS) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright restated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2024 earnings at ($0.73) EPS, Q3 2024 earnings at ($0.74) EPS, Q4 […]
More Stories
Lake Street Capital Begins Coverage on Anteris Technologies Global (NASDAQ:AVR)
Analysts at Lake Street Capital began coverage on shares of Anteris Technologies Global (NASDAQ:AVR – Get Free Report) in a...
Relx (NYSE:RELX) Now Covered by Analysts at Redburn Atlantic
Investment analysts at Redburn Atlantic assumed coverage on shares of Relx (NYSE:RELX – Get Free Report) in a research note...
Texas Roadhouse (NASDAQ:TXRH) Rating Lowered to “Hold” at Gordon Haskett
Texas Roadhouse (NASDAQ:TXRH – Get Free Report) was downgraded by analysts at Gordon Haskett from a “buy” rating to a...
The Toronto-Dominion Bank (TD) to Issue Quarterly Dividend of $1.05 on January 31st
The Toronto-Dominion Bank (TSE:TD – Get Free Report) (NYSE:TD) announced a quarterly dividend on Friday, January 10th,TickerTech Dividends reports. Investors...
West Pharmaceutical Services (NYSE:WST) Coverage Initiated by Analysts at Citigroup
Analysts at Citigroup assumed coverage on shares of West Pharmaceutical Services (NYSE:WST – Get Free Report) in a research note...
AngioDynamics (NASDAQ:ANGO) Updates FY 2025 Earnings Guidance
AngioDynamics (NASDAQ:ANGO – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share...